#AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma
#AAD26：赛诺菲在湿疹中披露三期OX40数据不及预期，出现第二例卡波西肉瘤

Sanofi on Saturday shared more mixed efficacy results from a Phase 3 atopic dermatitis program for its anti-OX40 ligand monoclonal antibody, further eroding Wall Street’s already waning confidence in the candidate.
赛诺菲周六公布其抗OX40配体单克隆抗体在一项三期特应性皮炎项目中的又一组参差不齐的疗效结果，进一步削弱了华尔街对该候选药物本已下滑的信心。